Protagonist Therapeutics (PTGX) Current Leases (2019 - 2026)

Protagonist Therapeutics (PTGX) has 8 years of Current Leases data on file, last reported at $2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 49.17% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at $2.3 million (up 49.17% YoY), and the FY2025 full-year result was $2.3 million, up 347.65% from the prior year.
• Current Leases improved to $2.3 million in Q1 2026, from $2.3 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $2.6 million in Q1 2023 to a low of $45000.0 in Q3 2024.
• A 5-year average of $1.8 million and a median of $2.3 million in 2022 frame the typical range for Current Leases.
• Across the five-year window, Current Leases slumped 97.5% in 2024 and jumped 4851.11% in 2025, its largest moves.
• Tracing PTGX's Current Leases over 5 years: stood at $2.5 million in 2022, then sank by 54.63% to $1.1 million in 2023, then plunged by 55.3% to $510000.0 in 2024, then surged by 347.65% to $2.3 million in 2025, then advanced by 2.45% to $2.3 million in 2026.
• Business Quant data shows PTGX's Current Leases at $2.3 million in Q1 2026, $2.3 million in Q4 2025, and $2.2 million in Q3 2025.